Showing 19,241 - 19,260 results of 74,121 for search '(( 50 ((nn decrease) OR (a decrease)) ) OR ( 5 ((we decrease) OR (mean decrease)) ))', query time: 0.92s Refine Results
  1. 19241

    EBBS frequencies, N = 517. by Anotida R. Hove (20513536)

    Published 2025
    “…Data were collected using the Pregnancy Physical Activity Questionnaire (PPAQ), Exercise Benefits and Barriers Scale (EBBS) and EQ-5D-5L. We used descriptive statistics and binary logistic regression for analyses. …”
  2. 19242

    EBBS summative indices, N = 517. by Anotida R. Hove (20513536)

    Published 2025
    “…Data were collected using the Pregnancy Physical Activity Questionnaire (PPAQ), Exercise Benefits and Barriers Scale (EBBS) and EQ-5D-5L. We used descriptive statistics and binary logistic regression for analyses. …”
  3. 19243

    Exercise Habits, N = 517. by Anotida R. Hove (20513536)

    Published 2025
    “…Data were collected using the Pregnancy Physical Activity Questionnaire (PPAQ), Exercise Benefits and Barriers Scale (EBBS) and EQ-5D-5L. We used descriptive statistics and binary logistic regression for analyses. …”
  4. 19244

    Adjusted odds ratios. by Anotida R. Hove (20513536)

    Published 2025
    “…Data were collected using the Pregnancy Physical Activity Questionnaire (PPAQ), Exercise Benefits and Barriers Scale (EBBS) and EQ-5D-5L. We used descriptive statistics and binary logistic regression for analyses. …”
  5. 19245

    Obstetric and health characteristics, N = 517. by Anotida R. Hove (20513536)

    Published 2025
    “…Data were collected using the Pregnancy Physical Activity Questionnaire (PPAQ), Exercise Benefits and Barriers Scale (EBBS) and EQ-5D-5L. We used descriptive statistics and binary logistic regression for analyses. …”
  6. 19246

    Physical activity summative indices, N = 517. by Anotida R. Hove (20513536)

    Published 2025
    “…Data were collected using the Pregnancy Physical Activity Questionnaire (PPAQ), Exercise Benefits and Barriers Scale (EBBS) and EQ-5D-5L. We used descriptive statistics and binary logistic regression for analyses. …”
  7. 19247

    Sociodemographic characteristics, N = 517. by Anotida R. Hove (20513536)

    Published 2025
    “…Data were collected using the Pregnancy Physical Activity Questionnaire (PPAQ), Exercise Benefits and Barriers Scale (EBBS) and EQ-5D-5L. We used descriptive statistics and binary logistic regression for analyses. …”
  8. 19248

    The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia by Daniel Landau (440830)

    Published 2018
    “…BM and proximal tibia EPOR were unchanged in C-A but decreased in CKD. Proximal tibial phospho-STAT5 increased after the EPO bolus in C but not in CKD.…”
  9. 19249
  10. 19250
  11. 19251
  12. 19252

    SDS pancreas senescence is downstream of p53-dependent changes in protein synthesis. by Marina E. Tourlakis (751986)

    Published 2015
    “…<p><b>A,</b> Increased nuclei per acinar area (*<i>P</i> = 0.029, Wilcoxon Rank Sum Test) and <b>B,</b> decreased mean acinus diameter (**<i>P</i> = 0.0073 and <i>NS</i> = not significant, <i>P</i> = 0.142; unpaired, two-sided T-test) in <i>Sbds</i><sup><i>P–/R126T</i></sup>; <i>Trp53</i><sup><i>–/–</i></sup>pancreas at 30 days of age. …”
  13. 19253

    Data_Sheet_1_Risk factors for admission to the pediatric critical care unit among children hospitalized with COVID-19 in France.docx by Blandine Prévost (13737820)

    Published 2022
    “…The CCU admission rate gradually decreased over the waves (from 31.0 to 17.8%). There were 32 (0.4%) deaths, of which the median age was 6 years (IQR: 177 days–15.5 years).…”
  14. 19254

    Image5_Lanatoside C decelerates proliferation and induces apoptosis through inhibition of STAT3 and ROS-mediated mitochondrial membrane potential transformation in cholangiocarcino... by Chao Zhang (51048)

    Published 2023
    “…</p><p>Methods: In this study, we extracted five cardiac glycosides (CGs) from natural plants: digoxin, lanatoside A, lanatoside C, lanatoside B, and gitoxin. …”
  15. 19255
  16. 19256
  17. 19257
  18. 19258
  19. 19259
  20. 19260

    Melanoma Expressed-CD70 Is Regulated by RhoA and MAPK Pathways without Affecting Vemurafenib Treatment Activity by Christine Pich (367328)

    Published 2016
    “…Interestingly, the clinical inhibitor of the common BRAF V600E/D variants, Vemurafenib (PLX-4032), which is currently used to treat melanoma patients with BRAF V600E/D-mutated metastatic melanomas, decreased CD70 expression in human CD70+ melanoma cell lines. …”